개방각녹내장 환자에서 트라보프로스트 0.003% 제제의 효과 및안전성
Effect and Safety of Travoprost 0.003% in Open Angle Glaucoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 트라보프로스트 0.003%가 트라보프라스트 0.004%와 비교하여 동등한 안압하강 효과를 가지면서 부작용을 줄여줄 수 있는지 알아보고자 한다. 대상과 방법: 2018년 1월부터 2018년 12월까지 본원에서 개방각녹내장으로 트라보프로스트 0.004%를 단독 점안 중인 환자 102명을 대상으로 트라보프로스트 0.003%로 교체하여 점안하였다. 트라보프로스트 0.003%로 교체 전과 교체 3개월 후에 안압과 결막충혈 정도, 각막미란 정도, 눈주위 색소침착 정도를 기록하였고, 환자가 느끼는 부작용을 비교하기 위해 충혈, 따가운 느낌, 가려움, 자극감, 시야흐림, 건조감, 이물감에 대한 설문지를 작성하였다. 결과: 트라보프로스트 0.003% 교체 전과 후의 안압은 12.95 ± 4.25 mmHg, 12.94 ± 3.89 mmHg로 유의한 차이가 없었으며(p=0.974), 각막미란 정도와 눈주위 색소침착은 유의한 차이가 없었으나 결막충혈 정도는 교체 전 1.60 ± 0.88에서 교체 후 1.36 ± 0.84로 유의하게 감소하였다(p=0.001). 설문조사 결과 환자가 느끼는 부작용의 정도는 충혈, 따가운 느낌, 가려움, 자극감, 이물감은 유의한 차이를 보이지 않았으나 시야흐림, 건조감은 점안제 교체 후 유의한 호전이 있었다(p=0.008, p=0.007). 결론: 트라보프로스트 0.003%는 트라보프로스트 0.004%와 동등한 안압하강 효과를 보이며 충혈의 정도를 감소시키고 시야흐림, 건조감의 주관적인 증상 호전을 보여 효과 및 안정성을 확인할 수 있었다.
Abstract
Purpose: To determine whether travoprost 0.003% has a similar intraocular pressure (IOP) reduction effect to that of travoprost0.004% while reducing side effects. Methods: This was a prospective study from January 2018 to December 2018 that included 102 patients diagnosed with openangle glaucoma who switched from travoprost 0.004% to travoprost 0.003%. We investigated the changes in IOP, conjunctivalhyperemia, corneal erosion, and eyelid pigmentation before and at 3 months after switching to travoprost 0.003%. Additionally,a questionnaire survey of these patients was conducted to determine possible side effects, including hyperemia, stinging, pruritus,irritation, blurred vision, dryness, and foreign body sensation. Results: IOP readings before and after switching to travoprost 0.003% were 12.95 ± 4.25 and 12.94 ± 3.89 mmHg, respectively,showing no significant change (p = 0.974). No changes were observed in corneal erosion or eyelid pigmentation; however, conjunctivalhyperemia was reduced significantly from 1.60 ± 0.88 to 1.36 ± 0.84 (p = 0.001). No significant changes in hyperemia,stinging, pruritus, irritation, or foreign body sensation were reported; however, a significant improvement was noted for blurredvision and dryness (p = 0.008, p = 0.007, respectively). Conclusions: We were able to show the effectiveness and safety of travoprost 0.003% as being as effective as travoprost0.004% in reducing IOP and injections while improving blurred vision and dryness.
참고문헌 (22)
- Bourne RR, "Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990-2010 : a meta-analysis", PLoS One, 11, pp.e0162229~ (2016)
- Leske MC, "Factors for glaucoma progression and the effect of treatment : the early manifest glaucoma trial", Arch Ophthalmol, 121, pp.48~56 (2003)
- Kass MA, "The Ocular Hypertension Treatment Study : a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma", Arch Ophthalmol, 120, pp.701~713 (2002)
- Toris CB, "Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes", Ophthalmology, 100, pp.1297~1304 (1993)
- European Glaucoma Society, "European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th edition-chapter 3:treatment principles and options supported by the EGS Foundation:Part 1: foreword; introduction; glossary; chapter 3 treatment principles and options", Br J Ophthalmol, 101, pp.130~195 (2017)
- Aptel F, "Efficacy and tolerability of prostaglandin analogs : a meta-analysis of randomized controlled clinical trials", J Glaucoma, 17, pp.667~673 (2008)
- Zimmerman TJ, "The impact of ocular adverse effects in patients treated with topical prostaglandin analogs : changes in prescription patterns and patient persistence", J Ocul Pharmacol Ther, 25, pp.145~152 (2009)
- Schulze MM, "The perceived bulbar redness of clinical grading scales", Optom Vis Sci, 86, pp.E1250~E1258 (2009)
- Bron AJ, "Grading of corneal and conjunctival staining in the context of other dry eye tests", Cornea, 22, pp.640~650 (2003)
- 이동욱, "비마토프로스트 점안 후 눈 주변 피부 색소침착이 발생한 환자에서 약물중단 후 경과", 대한안과학회지, 48(8), pp.1082~1087 (2007), 대한안과학회
- Fellman RL, "Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial", Ophthalmology, 109, pp.998~1008 (2002)
- Peace JH, "Polyquaternium-1-preserved travoprost 0.003% or benzalkonium chloride-preserved travoprost 0.004% for glaucoma and ocular hypertension", Am J Ophthalmol, 160, pp.266~274 (2015)
- Holló G, "The side effects of the prostaglandin analogues", Expert Opin Drug Saf, 6, pp.45~52 (2007)
- Chen J, "Bimatoprost : mechanism of ocular surface hyperemia associated with topical therapy", Cardiovasc Drug Rev, 23, pp.231~246 (2005)
- Figus M, "Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients", Eye(Lond), 28, pp.422~429 (2014)
- Guenoun JM, "In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells", Invest Ophthalmol Vis Sci, 46, pp.2444~2450 (2005)
- Wand M, "Latanoprost and periocular skin color changes", Arch Ophthalmol, 119, pp.614~615 (2001)
- Zhu W, "Effects of long-term antiglaucoma eye drops on conjunctival structures : an in vivo confocal microscopy study", J Ophthalmol, 2015, pp.165475~ (2015)
- Lee J, "Glaucoma and ocular surface disease", J Korean Glaucoma Soc, 8, pp.33~35 (2019)
- Mocan MC, "The association of chronic topical prostaglandin analog use with meibomian gland dysfunction", J Glaucoma, 25, pp.770~774 (2016)
- Stewart WC, "Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost", Am J Ophthalmol, 135, pp.314~320 (2003)
- Diaconita V, "Washout duration of prostaglandin analogues : a systematic review and meta-analysis", J Ophthalmol, 2018, pp.3190684~ (2018)